Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG7667 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RG7667 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Single/multiple doses |
| RG7667 | DRUG | Single/multiple ascending doses |
Inclusion Criteria: * Male and female subjects, 18 to 55 years of age, inclusive * Body mass index 18.0 to 31.0 kg/m2, inclusive * In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital signs, and laboratory values, as deemed by the Investigator E...
RG7667 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, and the completed trial evaluated its safety and tolerability in healthy participants. The drug is not approved for any indication and remains under investigation.
RG7667 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company conducted a Phase 1 study of the drug in healthy volunteers in the United States.
RG7667 is in Phase 1 clinical development. A single Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities, and its safety and efficacy are still being evaluated.
RG7667 has one completed clinical trial, NCT01496755, titled "A Study of RG7667 in Healthy Volunteers." This Phase 1, randomized, double-blind, placebo-controlled study enrolled 170 participants in the United States and included healthy adults aged 18 years and older.
RG7667 is not FDA approved. It is an investigational drug that has completed a Phase 1 trial in healthy volunteers. The drug is still in clinical development, and its safety and efficacy have not been established for any medical condition.